Oncotarget

CDK9 Inhibitors: A Promising Combination Partner in Treating Hematological Malignancies

Aug 9, 2023
Researchers discuss the potential of CDK9 inhibitors in treating hematological malignancies by targeting cancer-promoting genes like MYC and MCL1. Preclinical studies show promising results, with enitociclib demonstrating clinical activity in high-grade B lymphoma patients. CDK9 inhibitors may offer synergistic effects when combined with other drugs in the treatment of these malignancies.
Ask episode
Chapters
Transcript
Episode notes